Law­mak­ers’ ex­plo­sive charges turn a glob­al spot­light on Chi­na’s WuXi, and it’s feel­ing the heat

It doesn’t take a lot to dis­rupt a re­la­tion­ship be­tween a bio­phar­ma com­pa­ny and a glob­al CRO/CD­MO. From the small­est start­up shep­herd­ing a sin­gle drug in­to the clin­ic to a ma­jor phar­ma play­er look­ing for sub­stan­tial out­side help in R&D and man­u­fac­tur­ing, these con­trac­tu­al al­liances run for years, with enor­mous stakes on long-term projects.

Reg­u­la­to­ry is­sues, snags in pro­duc­tion, ques­tions about team lead­er­ship and lots more is­sues can sour the re­la­tion­ship at just about any time.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE